Metastatic Breast Cancer — ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer
Citation(s)
Randomized Phase II Study to Investigate the Efficacy, Safety and Tolerability of ZK 230211 (25 mg vs. 100 mg) as Second-line Endocrine Therapy for Postmenopausal Women With Hormone Receptor-positive Metastatic Breast Cancer